Trending Topic

< 1 min

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

This corrects the article: “Ioannou A. Evolution of Disease-modifying Therapy for Transthyretin Cardiac Amyloidosis. Heart International. 2024;18(1):30-37”. Two typography errors were included incorrectly due to an editorial error. In Table 1, “eplontersen” was incorrectly written as “eplomtersen”. This has been corrected in the text. In the section “Eplontersen”, the administration schedule should be written as […]

Use of a “CNI holidays” strategy in acute renal dysfunction late after heart transplant. Report of two cases

Pau Alonso, Ignacio Sánchez Lázaro, Luis Almenar, Luis Martínez-Dolz, Ana Andres, Antonio Salvador, Anastasio Montero
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Published Online: Aug 16th 2018 Heart International 2014;9(2):74-77 DOI: https://doi.org/10.5301/HEART.2014.12526
Select a Section…
1

Abstract

Overview

Background. Acute renal dysfunction (ARD) may appear in heart transplant (HTx) patients both in the early
postoperative period and during follow-up, even after several years. CD25 is a subunit of the interleukin-2
receptor which is found exclusively on activated CD4 T lymphocytes. CD25 is crucial for clonal expansion of
anti-allograft host lymphocytes that mediate in acute rejection. There are experiences supporting the use of
Anti-CD25 monoclonal antibodies (MAb) immediately after HTx in patients with ARD as a bridge to renal function
recovery, allowing the temporary suspension of treatment with CNI.
Methods. In this study we report two cases of successful use of weekly MAb (basiliximab) in HTx patients who
developed late ARD after HTx.
Conclusions. In coclusion, we think that in cases of ARD where CNI therapy plays a key role, the use of weekly
doses of basiliximab allows CNI discontinuation until the restoration of renal function is achieved.

Keywords

Basiliximab, CNI holiday, Heart transplant

2

Article Information

Disclosure

Financial support: No grants or funding have been received for this
study.

Correspondence

Pau Alonso La Fe University Hospital Bulevar sur s/n 46008 Valencia Valencia, Spain pau.alonso.fernandez@gmail.com

3

Further Resources

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF

This Functionality is for
Members Only

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

Close Popup